[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07546942":3,"trial-entities:NCT07546942":166,"trial-summary:NCT07546942":169},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":28,"primary_purpose":29,"phases":30,"enrollment_info":33,"interventions":36,"primary_outcomes":66,"secondary_outcomes":75,"sex":79,"minimum_age":80,"maximum_age":81,"healthy_volunteers":82,"eligibility_criteria":83,"std_ages":95,"locations":99,"central_contacts":112,"overall_officials":113,"references":114,"see_also_links":165},"NCT07546942","GARM-Autism Adults","Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.","Autism Spectral Disorder (ASD) In Adolescent-Adults Treated by Multimodal Protocol: IV Autologous cSVF, Interval IV Autologous MSCs (Cryopreserved), Strick Ketogenic Diet RESET Program, and Fecal Microbiota Transplantation (FMT)","ENROLLING_BY_INVITATION","2030-08-14","2026-04","2026-04-27","2026-04-30","Black Tie Medical, Inc.","INDUSTRY",true,"Autism spectrum disorder (ASD) is a neurodevelopmental condition with core deficits in social communication and behavior, often accompanied by gastrointestinal (GI) and metabolic dysfunction. Emerging evidence supports the role of neuroinflammation (including autoimmune components), gut-brain axis disruption, and metabolic dysregulation in ASD pathophysiology. Multimodal interventions targeting these pathways-using autologous cSVF, cryopreserved MSCs, FMT, and dietary modulation-intent is that these multimodal interventions may offer synergistic benefits for adolescents and adults with ASD.","This refined protocol integrates the latest evidence for a multimodal intervention-autologous cSVF, cryopreserved autologous MSCs, FMT, and a structured ketogenic protocol program-for adolescent and adult ASD management.\n\n1. Protocol Summary\n\n   Title:\n\n   A Phase 1-2 Randomized Controlled Trial Evaluating the Safety and Efficacy of Multimodal Therapy (Autologous cSVF + Cryopreserved Autologous MSCs, Fecal Microbiota Transplantation, Ketogenic Program Reset, and OT\u002FPT Training) in Adolescents and Adults with Autism Spectrum Disorder (ASD-Multi-level scoring)\n\n   Sponsor: Blacktie Principal Investigator: Robert W. Alexander, MD, FICS Study Phase: Phase I\u002FII Study Centers: 1-3 Clinical Applied Research Laboratories\u002Facademic centers with expertise in ASD, stem cell processing and utilization, plus gastroenterology\u002FPMD consultants available for FMT in patient's locale\n\n   Compliance:\n\n   NIH and IRB oversight Informed consent for all participants\n\n   \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n2. Background and Rationale Autism spectrum disorder (ASD) is a neurodevelopmental condition with core deficits in social communication and behavior, often accompanied by gastrointestinal (GI) and metabolic dysfunction. Emerging evidence supports the role of neuroinflammation (including autoimmune components), gut-brain axis disruption, and metabolic dysregulation in ASD pathophysiology. Multimodal interventions targeting these pathways-using autologous cSVF, cryopreserved MSCs, FMT, and dietary modulation-may offer synergistic benefits for adolescents and adults with ASD.\n\n   \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n3. Objectives and Endpoints\n\n   Primary Objective:\n\n   • Evaluate the safety and tolerability of the multimodal interventions compared to current standard of care (SOC) for supportive therapy.\n\n   Secondary Objectives:\n\n   • Assess changes in ASD core symptoms, GI function, behavioral and social outcomes, and quality of life.\n\n   Endpoints:\n   * Incidence of adverse events (AEs) and serious adverse events (SAEs)\n   * Change in validated ASD and GI symptom scales (CARS, VABS-II, GSRS, SRS, ABC)\n   * Microbiome diversity and metabolic biomarker changes\n   * Assessed performance and QoL evaluations\n4. Study Design and Methodology\n\n   * Design: Multi-disciplined, open labelled, controlled, parallel-group (1:1:1), tracked for cellular and biologics used, open-label, including tracking of diet\u002FOT-PT\n   * Sample Size: 50 participants (range ages 10-90, DSM-5 ASD diagnosis)\n   * Randomization: Stratified by age, sex, and baseline GI symptoms, Socialization\n   * Interim Analysis: Futility analysis at 50% enrollment\n5. Study Population\n\n   Inclusion Criteria:\n   * Age 10-90 years, DSM-5 ASD diagnosis\n   * Stable on current medications (if so treated at time of selection)\n   * With\u002Fwithout comorbid GI symptoms\n\n   Exclusion Criteria:\n   * Recent antibiotics\u002Fprobiotics\n   * Severe GI disease or malnutrition\n   * Recent major surgery\n   * Other Medical\u002FSurgery issues that preclude the treatment with the protocol; including spectrum limitations for patient tolerance or compliance.\n6. Intervention Protocols 6.1 Autologous Cellular Stromal Vascular Fraction (cSVF)\n\n   * Collection: Small volume Lipoaspirate via sterile microcannula harvesting of small aggregate tSVF - under local or supplemental anesthesia as dictated by patient ability to tolerate.\n   * Processing: Enzymatic digestion for cSVF and cellular isolation\u002Fconcentration of heterogeneous cell groups within the cSVF (via collagenase, centrifugation, and possible undesignated cell characterization (CD34+, CD90+, CD105+)\n   * Dosing: =\u002F\\> 10 x 106 - 5 × 10\\^7 cells delivered by standard Normal Saline IV infusion\n   * Administration: Intravenous (IV) route with in-line sterile 150u filtration\n   * Applied LED Red Light Exposure cSVF throughout deployment\n   * Standard American Cell Technology (ACT) protocol harvesting, testing and overnight shipping on day of Harvest for Cryopreservation Protocol for storage of autologous Mesenchymal Stem Cells (MSCs characterized as above) for future interval delivery\n   * Safety: Monitored for infusion reactions, infection, and thromboembolic events\\] 6.2 Cryopreserved Autologous MSCs\n   * Source: Autologous microcannula harvested tSVF or bone marrow (BMAC)\n   * Cryopreservation: Slow freezing (-1°C\u002Fmin to -80°C, then liquid nitrogen), 10% DMSO, clinical-grade solutions. ACT Standard and monitored storage per FDA requirement\n   * Viability: ≥70% post-thaw, confirmed by ORFLO Flow Cytometry\n   * Dosing: 1-30 × 10\\^6 cells within sterile Normal Saline (balanced) IV infusion minimum\n   * Administration: Peripheral IV route with in-line 150 u micron filtration and Red Light Therapy\n   * Quality Control: Surface marker analysis, sterility, \\[endotoxin, karyotype on record with FDA certified Cell Banking Laboratory- ACT\\] 6.3 Fecal Microbiota Transplantation (FMT)\n   * Donor Screening: Pathogen, parasite, and virus screening; FDA GMP processing\n   * Preparation: Standardized, frozen human gut microbiota, delivered on dry ice\n   * Pre-treatment: 14 days oral vancomycin, bowel cleanse (MoviPrep), acid suppression (Prilosec)\n   * Dosing: High initial dose (oral\u002Frectal), followed by daily oral maintenance for 7-8 weeks\n   * Monitoring: GI and behavioral symptoms (GSRS, CARS, SRS, VABS-II)14-17\\]\\] 6.4 Ketogenic\u002FCarnivore Diet (Carnivore RESET Program)\n   * Diet: High-fat, low-carbohydrate, animal-based reset; macronutrient ratios to induce a state of ketosis (indicative of fat burning and reduction of insulin resistance.\n   * Baseline Blood Testing: FBS, Fasting Insulin Levels, Hemoglobin A1c, Lipid Panel, Fasting Ketones, CBC, CRP, and other appropriate testing\n   * Monitoring: Dietary logs, blood ketones, nutritional assessments at least quarterly\n   * Support: PMC, Gastroenterologist,etc Provider or Dietitian, compliance checks near patient's home\n   * Repeat testing of Blood levels repeated at 90-180 days\n   * Safety: Monitor for metabolic derangements, GI side effects 6.5 OT\u002FPT Training\n   * Program: Standardized occupational and physical therapy modules\n   * Continuation of Verbal, Socialization, and Educational Efforts\n   * Frequency: 2-3 sessions\u002Fweek, individualized goals (may be home monitored)\n7. Safety Monitoring Plan\n\n   * Adverse Event Monitoring: Continuous, with prompt reporting of SAEs\n   * Infusion Reactions: Pre- and post-infusion monitoring for autologous cSVF\u002FMSCs\n   * Dietary Safety: Regular metabolic and nutritional assessments and tracking\n   * FMT Safety: Exclusion of high-risk participants, close monitoring for infection\n8. Outcome Measures and Biomarker Assessments Domain Assessment Tools\u002FMarkers ASD Symptoms CARS, SRS, ABC, VABS-II; observational behavior, socialization changes, communication abilities, GI Symptoms Bristol Stool Scale; Management testing of bowel flora bacteria Metabolic Blood glucose, ketones, vitamin B6, dopamine Inflammation Fecal calprotectin, serum IgA, ESR\u002FCRP Safety AE\u002FSAE logs, laboratory monitoring\n\n   \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n9. Statistical Analysis Plan\n\n   * Primary Analysis: Safety (AEs\u002FSAEs) by intervention Provider\n   * Secondary Analysis: Change in symptom scales and biomarkers (ANCOVA, mixed models)\n   * Interim Analysis: Futility and safety at 50% enrollment check\n10. Regulatory and Ethical Considerations\n\n    * FDA\u002FNIH Clinical Trial Submission: For Trial approval for use cSVF, MSCs, and FMT\n    * IRB Approval: NIH\u002FFDA Approval or equivalent recognized IRB Board (GARM International Review Board)\n    * Informed Consent: All participants\u002Fguardians\n    * Data Privacy: HIPAA-compliant data management",[19,20,21],"Autism Spectrum Disorder","Autism","Autism Spectral Disorder",[23,24,25,26,27],"Socialization","Learning Disability","Situational awareness and communication","Bowel dysfunction (flora correction)","cSVF and Cryopreserved MSCs (autologous)","INTERVENTIONAL","TREATMENT",[31,32],"PHASE1","PHASE2",{"count":34,"type":35},50,"ESTIMATED",[37,43,48,52,57,61],{"type":38,"name":39,"description":40,"armGroupLabels":41},"PROCEDURE","Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells","Isolation\u002Fconcentration autologous MSCs derived from tSVF from each patient participant only",[42],"ASD behavior, learning, communication and diet",{"type":44,"name":45,"description":46,"armGroupLabels":47},"DIETARY_SUPPLEMENT","Fecal Biomicrome Transplantation (FMT)","Novel Biome Protocol for elimination of patient's gut flora, replacement oral transplantation with a known flora common to restore the brain-gut balance in ASD patients",[42],{"type":44,"name":49,"description":50,"armGroupLabels":51},"Ketogenic RESET Diet Protocol","Limited timeframe strick ketogenic diet for RESET of insulin resistance in form of high animal derived protein, high animal derived fat, low carbohydrate diet for 90 days, then standard ketogenic diet as tolerated",[42],{"type":53,"name":54,"description":55,"armGroupLabels":56},"BEHAVIORAL","Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients","GI Axis modification of bowel flora (FMT); Diet modification to permit mild ketosis in patient; cellular modification with use of cSVF and MSCs (autologous only)",[42],{"type":44,"name":58,"description":59,"armGroupLabels":60},"FMT (Fecal Material Tranplantation)","Converting diet from patient selection which complies with the needs to change the GI-Axis to accommodate bowel changes and restoration of a normal bowel flora",[42],{"type":62,"name":63,"description":64,"armGroupLabels":65},"BIOLOGICAL","Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation","Use of cSVF isolation and submission to FDA certified tissue\u002Fcell bank for subsequent use of autolgous patient only",[42],[67,71],{"measure":68,"description":69,"timeFrame":70},"Socialization Alterations","SRS-2 caregiver\u002Fteacher: Change in social behavior as measured by the Social Responsiveness Scale, Second Edition (SRS-2), a 65-item caregiver- and teacher-reported instrument scored on a scale of 0 to 195, where lower scores indicate better social functioning. SRS-2 assessments are completed at baseline, 3 months, 6 months, and 12 months to evaluate change over time.Time Frame: Baseline, 3 months, 6 months, and 12 months","1 year",{"measure":72,"description":73,"timeFrame":74},"Communication\u002FEducation Enhancement","PPVT-5 Peabody Picture Vocabulary testing: Change in receptive vocabulary and language comprehension as measured by the Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5). Standard scores range from approximately 40 to 160 (mean = 100, SD = 15), where higher scores indicate better vocabulary and language ability. Testing is administered at baseline, 3 months, 6 months, and 12 months.Time Frame: Baseline, 3 months, 6 months, and 12 months","Months and 1 year",[76],{"measure":77,"description":78,"timeFrame":70},"Gut-Brain Axis Improvement","GSRS Testing: Change in gastrointestinal symptoms as measured by the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item patient- or caregiver-reported questionnaire. Scores range from 1 to 7 per item (total composite score 15-105), where lower scores indicate fewer or less severe GI symptoms. Assessed at baseline, 3 months, 6 months, and 12 months.Time Frame: Baseline, 3 months, 6 months, and 12 months","ALL","10 Years","90 Years",false,{"inclusion":84,"exclusion":88,"raw_text":94},[85,86,87],"ADS","Stable on current medications or therapy","With\u002Fwthout comorbid GI (gut\u002FAxis) symptoms",[89,90,91,92,93],"Recent antiobiotics or probiotic therapy within 30 days","Severe GI disease or malnutrition","Recent major surgery that may interfere with study course","Other Med\u002FSurgery issues that may preclude treatment with this protocol","Inability to perform the monitoring of FMT without supervision by qualfied Provider","Inclusion Criteria:\n\n* ADS\n* Stable on current medications or therapy\n* With\u002Fwthout comorbid GI (gut\u002FAxis) symptoms\n\nExclusion Criteria:\n\n* Recent antiobiotics or probiotic therapy within 30 days\n* Severe GI disease or malnutrition\n* Recent major surgery that may interfere with study course\n* Other Med\u002FSurgery issues that may preclude treatment with this protocol\n* Inability to perform the monitoring of FMT without supervision by qualfied Provider",[96,97,98],"CHILD","ADULT","OLDER_ADULT",[100,109],{"facility":101,"city":102,"state":103,"zip":104,"country":105,"geoPoint":106},"Regenevita Health","Hamilton","Montana","59840","United States",{"lat":107,"lon":108},46.24687,-114.16037,{"facility":110,"city":102,"state":103,"zip":104,"country":105,"geoPoint":111},"Robert W. Alexander, MD, FICS",{"lat":107,"lon":108},[],[],[115,118,120,122,125,128,131,134,137,140,143,145,148,151,154,157,160,162],{"type":116,"citation":117},"BACKGROUND","Alexander, Robert W. Overview of COVID-19 Lung Damage Clinical Trial NCT#04326036 Using Cellular Stromal Vascular Fraction (cSVF) and Functional Respiratory Imaging (FRI) Analysis of Pulmonary Injury & Post-Viral (SARS-Cov-2) Adult Respiratory Distress Syndrome (ARDS). Ann Stem Cell Res Ther. 2020; 4(1): 1039.",{"type":116,"citation":119},"Alexander, Robert W. Overview of Cellular Stromal Vascular Fraction (cSVF) & Biocellular Uses of Stem\u002FStromal Cells and Matrix (tSVF + HD-PRP) in Regenerative Medicine, Aesthetic Medicine and Plastic Surgery. J. Stem Cell Res Dev Ther. 2019; 4:1-15.",{"type":116,"citation":121},"Alexander, Robert W., Everts, Peter A. Understanding Communication Between Cellular Stromal Vascular Fraction (cSVF), Mesenchymal Stem Cells (MSC), Pericytes, Blood Derivative (HD PRP): Mechanisms in Inflammation and Immune Modulation. 2026; J Stem Cell Res. 7(1)-81. DOI:http:doi.org\u002F10.52793\u002FJSCR.2026.7(7(1)-81.",{"pmid":123,"type":116,"citation":124},"32819434","Li Y, Luo ZY, Hu YY, Bi YW, Yang JM, Zou WJ, Song YL, Li S, Shen T, Li SJ, Huang L, Zhou AJ, Gao TM, Li JM. The gut microbiota regulates autism-like behavior by mediating vitamin B6 homeostasis in EphB6-deficient mice. Microbiome. 2020 Aug 20;8(1):120. doi: 10.1186\u002Fs40168-020-00884-z.",{"pmid":126,"type":116,"citation":127},"31150625","Sharon G, Cruz NJ, Kang DW, Gandal MJ, Wang B, Kim YM, Zink EM, Casey CP, Taylor BC, Lane CJ, Bramer LM, Isern NG, Hoyt DW, Noecker C, Sweredoski MJ, Moradian A, Borenstein E, Jansson JK, Knight R, Metz TO, Lois C, Geschwind DH, Krajmalnik-Brown R, Mazmanian SK. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019 May 30;177(6):1600-1618.e17. doi: 10.1016\u002Fj.cell.2019.05.004.",{"pmid":129,"type":116,"citation":130},"23852569","Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013 Aug;15(8):337. doi: 10.1007\u002Fs11894-013-0337-1.",{"pmid":132,"type":116,"citation":133},"39343920","Wang J, Li R. Effects, methods and limits of the cryopreservation on mesenchymal stem cells. Stem Cell Res Ther. 2024 Sep 29;15(1):337. doi: 10.1186\u002Fs13287-024-03954-3.",{"pmid":135,"type":116,"citation":136},"35592426","Xie J, Ekpo MD, Xiao J, Zhao H, Bai X, Liang Y, Zhao G, Liu D, Tan S. Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine. Front Pharmacol. 2022 May 3;13:907943. doi: 10.3389\u002Ffphar.2022.907943. eCollection 2022.",{"pmid":138,"type":116,"citation":139},"37662694","Ferreira MY, Carvalho Junior JDC, Ferreira LM. Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF). Regen Ther. 2023 Aug 26;24:332-342. doi: 10.1016\u002Fj.reth.2023.08.003. eCollection 2023 Dec.",{"pmid":141,"type":116,"citation":142},"33203028","Wragg NM, Tampakis D, Stolzing A. Cryopreservation of Mesenchymal Stem Cells Using Medical Grade Ice Nucleation Inducer. Int J Mol Sci. 2020 Nov 13;21(22):8579. doi: 10.3390\u002Fijms21228579.",{"type":116,"citation":144},"Bradstreet, J.J. et al. Cell Transplant. 2014: 23:1 suppl): 105-112",{"pmid":146,"type":116,"citation":147},"30112846","Park EH, Lim HS, Lee S, Roh K, Seo KW, Kang KS, Shin K. Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial. Stem Cells Transl Med. 2018 Sep;7(9):636-642. doi: 10.1002\u002Fsctm.18-0031. Epub 2018 Aug 15.",{"pmid":149,"type":116,"citation":150},"34836612","Brinkman FSL, Winsor GL, Done RE, Filloux A, Francis VI, Goldberg JB, Greenberg EP, Han K, Hancock REW, Haney CH, Haussler S, Klockgether J, Lamont IL, Levesque RC, Lory S, Nikel PI, Porter SL, Scurlock MW, Schweizer HP, Tummler B, Wang M, Welch M. The Pseudomonas aeruginosa whole genome sequence: A 20th anniversary celebration. Adv Microb Physiol. 2021;79:25-88. doi: 10.1016\u002Fbs.ampbs.2021.07.001. Epub 2021 Nov 16.",{"pmid":152,"type":116,"citation":153},"40442857","Nguyen LT, Nguyen PM, Nguyen HP, Bui HT, Dao LTM, Van Pham M, Hoang CK, Nguyen PT, Nguyen TTP, Nguyen ATP, Hoang VT, Bui HTP, Vuong NK, Van Ngo D. Outcomes of autologous bone marrow mononuclear cell administration combined with educational intervention in the treatment of autism spectrum disorder: a randomized, open-label, controlled phase II clinical trial. Stem Cell Res Ther. 2025 May 30;16(1):268. doi: 10.1186\u002Fs13287-025-04404-4.",{"pmid":155,"type":116,"citation":156},"31477562","Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019 Sep;47:529-542. doi: 10.1016\u002Fj.ebiom.2019.08.032. Epub 2019 Aug 30.",{"pmid":158,"type":116,"citation":159},"28122648","Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, Khoruts A, Geis E, Maldonado J, McDonough-Means S, Pollard EL, Roux S, Sadowsky MJ, Lipson KS, Sullivan MB, Caporaso JG, Krajmalnik-Brown R. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017 Jan 23;5(1):10. doi: 10.1186\u002Fs40168-016-0225-7.",{"type":116,"citation":161},"Galipeau, J, et al. J Translat Med, 2019: 17:397",{"pmid":163,"type":116,"citation":164},"34515938","Villarreal-Martinez L, Gonzalez-Martinez G, Saenz-Flores M, Bautista-Gomez AJ, Gonzalez-Martinez A, Ortiz-Castillo M, Robles-Saenz DA, Garza-Lopez E. Stem Cell Therapy in the Treatment of Patients With Autism Spectrum Disorder: a Systematic Review and Meta-analysis. Stem Cell Rev Rep. 2022 Jan;18(1):155-164. doi: 10.1007\u002Fs12015-021-10257-0. Epub 2021 Sep 13.",[],{"nct_id":4,"conditions":167,"biomarkers":168},[19],[],{"nct_id":4,"found":82,"summary":170,"prompt_version":170},null]